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Abstract
The transcription factor Elf3, which is one of over 25 Ets family members, is expressed in a wide variety of carcinomas and has been
shown to promote the transcription of many genes implicated in cancer. To understand how the Elf3 gene is regulated at the transcriptional
level, we probed its 5V-flanking region, and we report here the identification of both proximal and distal regions that regulate murine Elf3
promoter activity. In addition to mapping the transcription start site of the Elf3 gene, the work described in this study identifies four cis-
regulatory elements in the proximal promoter region of the gene. These include a cis-regulatory element previously designated ESE, a nB
site, a POU motif, and a CCAAT box. In addition, we demonstrate that a novel 94 bp region 2 kb upstream of the transcription start site
significantly elevates Elf3 promoter activity in F9-differentiated cells, but not in the parental F9 embryonal carcinoma (EC) cells. This region
appears to be largely responsible for the increase in Elf3 promoter activity that accompanies the differentiation of embryonal carcinoma cells.
D 2004 Elsevier B.V. All rights reserved.
Keywords: Ets proteins; Differentiation; Gene regulation; Distal enhancer; ESX; ESE1; ERT; Jen
1. Introduction
Transcription factors belonging to the Ets family play
critical roles in normal growth and development, as well
as human malignancy (Dittmer and Nordheim, 1998).
Since the discovery of the first Ets family member, over
50 Ets genes have been identified, and at least 25 are
expressed in mammals (Laudet et al., 1999). One Ets
family member, Elf3 (also known as ESX, ESE-1, ERT,
and JEN), is expressed ubiquitously by epithelial cells
(Chang et al., 1997; Oettgen et al., 1997; Tymms et al.,
1997), but it also can be induced in other cell types under
pathological conditions (Grall et al., 2003). The roles of
Elf3 have been examined recently in both cell culture and
animal models. Inactivation of both alleles of Elf3 by gene
targeting leads to fetal lethality (Ng et al., 2002). Approx-
imately 30% of the null fetuses die around embryonic day
11.5. The 70% that survive to birth exhibit severe alter-
ations in the cellular architecture of the small intestine,
including poor villus formation and defective terminal
differentiation of the mucus-secreting goblet cells and
the absorptive enterocytes. Moreover, enterocytes from
Elf3 null animals express significantly reduced levels of
type II TGF-h-receptor (ThR-II) at both the RNA and the
protein level. Similarly, reduction of Elf3 in a colon cancer
cell line by use of an Elf3 antisense retroviral construct
0378-1119/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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also reduced TbR-II expression (Lee et al., 2003). Other
studies have linked Elf3 directly to TbR-II transcription in
epithelial cells by its binding to two essential ets-sites in
the TbR-II promoter (Choi et al., 1998; Kim et al., 2002;
Kopp et al., 2004). In addition to the TbR-II gene, Elf3
has been implicated in the regulation of multiple genes,
including endo A, SPRR2A, SPRRIB, and nitric-oxide
synthase (Oettgen et al., 1997; Rudders et al., 2001;
Reddy et al., 2003).
Elf3 also appears to play important roles in cancer, and it
is aberrantly expressed in cancers of the lung and breast
(Chang et al., 1997). In the lung, elevated Elf3 expression
has been implicated in the expression of the SPRRIB gene, a
marker for early metaplastic alterations in bronchial epithe-
lium (Reddy et al., 2003). In breast cancer, the 1q32
chromosomal region containing Elf3 (Chang et al., 1997)
is amplified in 50% of early tumors (Isola et al., 1995).
However, in the case of Hs578t breast cancer cells, Elf3 is
expressed at very low levels. Elevating the expression of
Elf3 in Hs578t cells dramatically elevates the expression of
TbR-II and decreases the tumorigenicity of these cells
(Chang et al., 2000).
Given the important roles of Elf3 in normal cellular
physiology and cancer, it is important to determine how
transcription of the Elf3 gene is regulated. Sequence
analyses of the Elf3 gene have identified several poten-
tial transcription factor binding sites in its promoter
region, including ets, POU, USF, and nB sites, as well
as GC, CCAAT, and TATA boxes (Neve et al., 1998;
Oettgen et al., 1999). Thus far, only the nB site and a
novel site, termed an ESE element, in the human ELF3
gene have been shown to be functional (Rudders et al.,
2001; Park et al., 2001). Importantly, other regions of
the Elf3 gene have not been examined for their effects
on its transcription.
The aim of this study was to identify and characterize cis-
acting regions of the murine Elf3 gene that control its
transcription in early embryonic tumor cells. This work
was conducted using murine embryonal carcinoma (EC)
cells and their retinoic acid (RA) induced differentiated
counterparts, because the steady-state levels of Elf3 mRNA
increase at least sixfold when F9 EC cells differentiate (Kim
et al., 2002). Currently, it is unknown whether increases in
Elf3 expression influence the differentiation of EC cells, but
it is believed to play an important role in the increase in
transcription of the TbR-II gene after EC cells differentiate
(Kim et al., 2002).
In this study, we have identified two regions of the Elf3
gene that influence the activity of its promoter. Initially, we
mapped the transcription start site of the gene in F9-
differentiated cells and tested the function of six potential
cis-regulatory elements in the proximal promoter region of
the murine Elf3 gene. Importantly, we also demonstrate
that differentiation substantially increases the activity of
the Elf3 promoter and that this increase in promoter
activity is due in large measure to a novel regulatory
region located approximately 2 kb upstream of the tran-
scription start site.
2. Materials and methods
2.1. Cell culture, transfection and luciferase assay
F9 EC cells were cultured on gelatinized dishes in Dul-
becco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (HyClone,
Logan, UT) and antibiotics (Kim et al., 2002; Nowling et
al., 2003). Unless otherwise stated, all chemicals were
purchased from Sigma (St. Louis, MO). F9 EC cells were
transfected on the day after being seeded at 20,000 cells/well
in 24-well plates. For transfection of F9-differentiated cells,
F9 EC cells were seeded at 4000 cells/well in 24-well plates
and treated with 5 AM RA to induce differentiation. The
differentiated cells were transfected 3 days later. Transfec-
tions were performed with Lipofectamine and the Plus
transfection reagent (Invitrogen) according to the manufac-
turer’s instructions using 400 ng of Elf3 promoter-luciferase
plasmids and 200 ng of pRL-TK internal control vector
(Promega, Madison, WI). Cells were harvested 24 h after
transfection, luciferase activity was measured using a Dual-
luciferase reporter assay kit (Promega) with a Luminoskan
RS plate-reading luminometer (MTX Lab Systems, Vienna,
VA), and activities were normalized to the activity of an
internal control vector, pRL-TK. Values are presented as the
meanF standard error of the mean (S.E.M.) of duplicate or
triplicate samples.
2.2. Sequencing
The LI-COR and ABI Sequencers at the Genomics Core
Research Facility at the University of Nebraska at Lincoln
were used along with primer walking to sequence the 5V-
flanking region of the mouse Elf3 gene. Both strands were
sequenced. The ABI sequencer was also used to verify
critical sequences in various plasmids.
2.3. Mapping the transcription start site by rapid
amplification of cDNA ends (5V-RACE)
The transcription start site of the murine Elf3 gene was
determined using 5V-RACE. Two internal primers, 5V-
TCTCCCAGAGGTCCAAAGACTAGC-3V (nucleotide po-
sition 378 to 401) and 5V-AGCTCCTCCAGCGCA-
CAGCTGCAGAGGGTGGCTCC-3V (nucleotide position
340 to 374), were designed based on the Elf3 cDNA sequence
(GenBank NM-007921). These two primers were used in
conjunction with the RLM 5V-RACE adapter primer
(Ambion, Austin, TX) to capture the 5V end of the Elf3
mRNA. The resulting fragments were cloned into the
pSP72 vector (Promega). The inserts of 17 recombinant
clones were sequenced.
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2.4. Generation of promoter/reporter gene constructs
The Elf3 promoter region  338 to + 122 was amplified
by PCR from genomic DNA of F9-EC cells. Restriction sites
NheI and BglII were incorporated at the ends of the PCR
primers to allow insertion into the pGL3-luciferase reporter
vector (Promega). PCR primers were designed based on the
promoter region sequence from Neve et al. (1998) 5V-
GTAGCTAGCGCCAGGCCCCCAGGAAGA-3V (sense)
and the cDNA sequence of Tymms et al. (1997) 5V-GTAA-
GATCTGGTGTGGCAGGCGGGTGA-3V (antisense). To
mutate potential cis-regulatory elements within this se-
quence, site-directed mutagenesis of the Elf3 promoter
Luciferase construct was performed using the ‘‘quick
change method’’, as described previously (Kim et al.,
2002; Nowling et al., 2003). The following primers were
used along with their reverse complements: 5V-
CAGATTCTGACAATCATTAAAACTCGAGGCCT-
CTGATTTCCAG-3V for ESEmut; 5V-CAGGAAATCCC-
CAGCATCTCGAGAGCCACCAGCTCAGGTTAC-3V for
CCAATmut ; 5V-AAGTGGCACGGAATATGAATT-
TCACCTGGGACAGGGAGCCCAG-3V for POUmut; and
5V-GGGAGCCCAGTCTGAAGGCCAGTTAATTAA-
CAGCATCCAATGAGC-3V for jBmut. The bolded nucleo-
tides are the mutations introduced into the sequence. All
promoter sequences were verified by DNA sequencing.
The region of the mouse Elf3 gene from  2898 to
+ 703 was inserted into the pGL3-Basic vector between
the MluI and HindIII sites to generate the promoter/
reporter construct, mElf3 2898/ + 703. Additional pro-
moter/reporter gene constructs lacking portions of this
sequence were constructed by digestion with pairs of
restriction enzymes, blunting with klenow, and religa-
tion. Thus, mElf3 2437/ + 703 was generated using
MluI and KpnI, mElf3 2347/ + 703 using MluI and
BglII, mElf3 2012/ + 703 using MluI and EcoRI, and
mElf3  2898/ + 703D 2343/  2013 using BglII and
EcoRI.
To generate mElf3 338/ + 703, the promoter region
upstream of + 32 was removed from mElf3 2898/ + 703
and the fragment  338/ + 32 was obtained from
mElf3 338/ + 122 by digestion with KpnI (at an upstream
polylinker site) and MscI. The  338/ + 32 fragment was
then inserted into what was left of mElf3 2898/ + 703.
Additional promoter/reporter constructs were made by
inserting various sequences between the KpnI and NheI
restriction sites upstream of the promoter in mElf3 338/
+ 703. Three constructs made in this manner using sequen-
ces generated by PCR from mElf3 2898/ 703 were
mEl f3  2347 / + 703D 2 0 1 2 /  3 3 9 , mEl f3  2347 /
+ 703D 2211/ 339, and mElf3 2236/ + 703D 2142/ 339.
Another series of constructs made in this manner included
various mutations of the Elf3 sequence from  2236 to
 2143. These mutations were substitutions of ‘CCCGGG’
in each of 15 positions in the sequence (or ‘CGG’ in place
of the first three bases). In these cases, the sequences to be
inserted were obtained by synthesis of smaller overlapping
oligonucleotides, which were extended using taq polymer-
ase. All promoter sequences were verified by DNA
sequencing.
The promoter/reporter construct, mElf3  2347/
+ 703D 2012/  339, was used in turn to generate two
additional constructs. mElf3 2347/ + 703D 2012/  339
was digested with pairs of restriction enzymes, KpnI and
EcoRI or EcoRI and NheI, to produce mElf3 2093/
+ 703D 2012/  339 and mElf3 2347/ + 703D 2089/  339,
respectively, after blunting with klenow and religation.
All promoter sequences were verified by DNA sequencing.
3. Results
3.1. Sequence of the murine Elf3 5V-flanking region
The primary objective of this study was to identify
regions of the Elf3 gene required for its transcription. To
initiate this study, the murine Elf3 gene from  2898 to
+ 703 was sequenced. This sequence has been assigned
the GenBank accession number AY456682. To facilitate
comparison with previous studies, we have designated
the nucleotide positions in this report according to the
numerical system of Neve et al. (1998), who presented
an alignment of the human ELF3 and murine Elf3
promoters between  347 and + 50 of the murine
sequence.
3.2. Mapping the transcription start site of the murine Elf3
gene
The only published report concerning the transcription
start site of the murine Elf3 gene places it 50 bp
downstream from a consensus TATA box (Tymms et
al., 1997). However, functional TATA boxes typically
direct transcriptional initiation to locations 30F 2 bp
downstream (Bucher, 1990). Therefore, we mapped the
location of the transcription start site of the murine Elf3
gene in F9-differentiated cells. For this purpose, 5V-
RACE was used. Seventeen clones were isolated and
sequenced, and a dominant transcriptional initiation site
(16 out of 17 clones) was identified at nucleotide + 32
(Fig. 1). This site is 30 bp downstream of the putative
TATA box located at + 2. The sequence of the 17th
clone in our study corresponds to a start site at nucle-
otide + 33, and it could have resulted from premature
termination during the polymerization step. Thus, it
appears that one major start site is employed in F9-
differentiated cells. Interestingly, sequence analysis of our
17 clones identified both splice variants of Elf3 mRNA,
Elf3a and Elf3b, observed previously in the adult lung of
mice (Tymms et al., 1997). Thus, both Elf3a and Elf3b,
which differ by 20 amino acids, may be expressed in F9-
differentiated cells.
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3.3. The proximal promoter region of Elf3 contains at least
four cis-regulatory elements
To identify essential cis-regulatory elements in the murine
Elf3 gene, we inserted the region between  338 and + 122
of the Elf3 gene into the promoterless luciferase reporter gene
construct, pGL3 Basic, to create mElf3 338/ + 122. This
construct exhibited 100-fold higher luciferase activity than
the parent pGL3 Basic vector (data not shown). Previous
analysis of this region (Neve et al., 1998) identified several
potential cis-regulatory elements, including a GC box, a USF
site, a POUmotif, a nB site and a CCAAT box. Of these, only
the nB site has been shown to be functional in the human
ELF3 gene (Rudders et al., 2001). In addition, a novel cis-
regulatory element referred to as ESE was identified recently
in the human ELF3 gene and shown to act as a positive cis-
regulatory element in a human gastric cancer cell line (Park et
al., 2001). To determine whether any of these potential
regulatory sequences are functional in the murine Elf3 gene,
each of these sites were disrupted individually in the Elf3
promoter/reporter gene construct mElf3 338/ + 122. Dis-
ruption of the ESE element and the nB site reduced promoter
activity by 48% and 43%, respectively (Fig. 2). Larger
reductions in promoter activity were observed when the
POU motif and CCAAT box were mutated, 65% and 71%,
respectively. However, disruption of the two GC boxes or the
USF site did not reduce Elf3 promoter activity (data not
shown). Thus, the proximal promoter region of the Elf3 gene
contains at least four cis-regulatory elements that influence its
activity, a CCAAT box, a nB site, a POU motif and ESE.
3.4. Differentiation of F9 EC cells elevates Elf3 promoter
activity
Previous studies demonstrated that differentiation of F9
EC cells leads to significant increases in the steady-state
levels of Elf3 mRNA (Kim et al., 2002). Therefore, we
examined whether the activity of the Elf3 promoter
increases when EC cells differentiate. Initially, this was
examined by transiently transfecting F9 EC cells with
mELF3 338/ + 122. Five hours after transfecting the cells,
the medium was changed and RAwas added to one set of F9
EC cells to induce differentiation. In comparison to the
untreated F9 EC cells, Elf3 promoter activity increased
approximately twofold after a 3-day exposure to RA (Fig.
3A). This was significantly lower than the sixfold increase
in Elf3 mRNA observed previously when F9 EC cells
differentiate (Kim et al., 2002). This raised the possibility
that other regions of the Elf3 gene are required for full
promoter activity in F9-differentiated cells. To examine this
possibility, we generated a murine Elf3 promoter/reporter
gene construct that contains a larger region of the Elf3 gene.
Fig. 1. Nucleotide sequence of the region containing the murine Elf3 transcription start site. The transcription start site of murine Elf3 in F9-differentiated cells
was determined by 5V-RACE as described in Materials and methods. The major transcription start site is indicated by an arrow. Other sequences of interest are
boxed, including potential ESE, POU, and nB elements and CCAAT and TATA boxes.
Fig. 2. Murine Elf3 promoter/reporter activity in F9-differentiated cells. Promoter/reporter constructs with potential cis-regulatory sites mutated (as indicated
with an ‘‘X’’) were transiently transfected into F9-differentiated cells and assayed for luciferase activity after 48 h as described in Materials and methods.
Results were normalized with an internal control and expressed relative to the activity of the unmutated, wild-type, construct mElf3 338/ + 122. Values shown
are averagesF S.E.M. for duplicate samples in a representative experiment. This experiment was performed three times with similar results.
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Specifically, we inserted the region  2898 to + 703 into
the promoterless vector pGL3 Basic to generate mElf3
2898/ + 703. When this construct was transfected into F9 EC
cells, we observed a fivefold increase in promoter activity
for F9 cells exposed to RA for 3 days (Fig. 3A). To confirm
and extend these findings, we directly compared the activity
of mElf3 2898/ + 703 to that of mELF3 338/ + 122.
There was no significant difference between the activity
of the larger and the smaller Elf3 promoter/reporter gene
constructs when they were transiently transfected into F9
EC cells (Fig. 3B). In contrast, when F9 EC cells were
transfected after 3 days of RA-induced differentiation, the
activity of the larger construct was fivefold higher than
the activity of the smaller mElf3338/ + 122 construct
(Fig. 3B). Together, these findings argue that at least one
region outside the proximal promoter exerts a strong
influence on Elf3 promoter activity in F9-differentiated
cells.
3.5. An upstream regulatory region elevates Elf3 promoter
activity
To identify the sequences responsible for elevated pro-
moter activity, we examined the sequences between  2898
and  339 and between + 122 and + 703 for their contribu-
tion to Elf3 promoter activity. Initially, we created the
promoter/reporter gene construct, mElf3 338/ + 703 and
compared its activity to that of mElf3 338/ + 122. In F9-
differentiated cells, the activity of mElf3 338/ + 703 was
only slightly higher (approximately twofold) than that of
mElf3 338/ + 122 (data not shown). Therefore, we focused
our attention on the region between  2898 and  339.
Additional studies in the future will be needed to identify
regulatory sequences located between + 123 and + 703.
To identify sequences upstream of  338 that influence
Elf3 promoter activity, progressively larger amounts of the
Elf3 gene between  2898 and  2012 were deleted from 5V
end of the promoter/reporter gene construct mElf3 2898/
+ 703. Removal of the region between  2898 and  2347
did not reduce Elf3 promoter activity (Fig. 4A). However,
deletion of the region upstream of  2012 reduced Elf3
promoter activity (Fig. 4A). This suggested that the region
of the Elf3 gene between  2347 and  2012 contained one
or more cis-regulatory elements that influence its promoter
activity in F9-differentiated cells. This possibility was tested
by deleting the region  2343 to  2013 to generate the
construct mElf3 2898/+ 703D 2343/ 2013. When this con-
struct was transfected into F9-differentiated cells, the lucif-
erase activity generated was approximately fourfold lower
than that observed with the parent, mElf3 2898/ + 703,
construct (Fig. 4A).
The region between  2347 and  2012 was examined
further using five additional promoter/reporter gene con-
structs, which incorporated portions of this region inserted
into mElf3 338/ + 703 upstream of the proximal promoter
(Fig. 4B). Importantly, mElf3 2236/ + 703D 2142/  339,
incorporating the 94 bp sequence from  2236 to
 2143, exhibited nearly fourfold greater activity than
mElf3 338/ + 703. To verify the importance of the 94
bp region in the upregulation of the Elf3 promoter when
F9 EC cells undergo differentiation, we compared the
activity of mElf3 2236/ + 703D 2142/ 339 to that of
mElf3 338/ + 703 in F9 EC cells and F9-differentiated
cells. As expected, there was no difference in the
activity of these two constructs in F9 EC cells, whereas
mElf32236/ + 703D 2142/  339 exhibited greater than
sixfold higher activity in F9-differentiated cells (Fig.
4C). Hence, we focused the remainder of our efforts
Fig. 3. An upstream distal enhancer significantly increases Elf3 promoter activity in F9-differentiated cells. F9 EC cells were transfected with either a short
 338/ + 122 or a long  2898/ + 703 Elf3 promoter/reporter construct as described in Materials and methods. (A) F9 EC cells were transfected with the Elf3
promoter/reporter gene constructs shown. Five hours after transfection, half of the cells were induced to differentiate with 5 AM RA. Luciferase assays were
conducted 24, 48 or 72 h after transfection as described in Materials and methods. Results from duplicate F9 EC samples were averaged and used with
individual differentiated cell samples to generate ratios of luciferase activity (F9-differentiated: F9 EC). The averageF S.E.M. of these ratios is plotted. This
experiment was repeated with triplicate samples with similar results. (B) F9 EC and F9-differentiated cells were transfected independently. AveragesF S.E.M.
are plotted for representative experiments, which were repeated multiple times with similar results.
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in this study on the 94 bp sequence between  2236
and 2143.
3.6. A 36 bp upstream region is required for elevated Elf3
promoter activity
To identify specific DNA sequences within the sequence
from  2236 to  2143 that are responsible for elevating
Elf3 promoter activity, saturation mutagenesis was em-
ployed. Specifically, one 3 bp mutant and fifteen 6 bp
mutants were generated to sequentially disrupt the entire
94 bp sequence (Fig. 5A). For this purpose, the wild-type
sequence for each of the fifteen 6 bp mutants was replaced
with the sequence 5V-CCCGGG-3V. After transient transfec-
tion into F9-differentiated cells, the activity of each mutant
construct was compared to the activity of mElf3 2236/
Fig. 4. Progressive deletion analysis of the Elf3 upstream flanking region. Promoter/reporter constructs containing the indicated regions of upstream flanking
sequence were transfected into F9-differentiated cells and assayed for luciferase activity as described in Materials and methods. (A) Means from three similar
experiments, each with triplicate samples expressed relative to mElf3 338/ + 122, were used to generate averagesF S.E.M. (B) Means from five similar
experiments, each with triplicate samples expressed relative to mElf3 338/ + 703, were used to generate averagesF SEM. (C) F9 EC and F9-differentiated
cells were transfected independently with either mElf3 338/ + 703 or mElf3 2236/ + 703D 2142/ 339 Elf3 promoter/reporter construct. For the purpose of
comparison, the activity of the mElf3 338/ + 703 was set to 1. The values shown are averagesF S.E.M. for triplicate samples from a representative
experiment. This experiment was repeated and similar results were obtained.
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+ 703D 2142/  339. This experiment identified a contiguous
core of 36 bp (mutants #5 through #10,  2215 to  2180)
that influenced Elf3 promoter activity (Fig. 5B). Each of the
six mutant constructs, which encompass this 36 bp region,
reduced promoter activity. The largest reduction was ob-
served with mutant #9, which eliminated nearly all the
activity of the 94 bp sequence.
Thus far, efforts to identify the factors that bind to this 36
bp region have not been successful. Surprisingly, electro-
phoretic mobility shift assay (EMSA) failed to demonstrate
specific binding to this region by any factors in nuclear
extracts from F9-differentiated cells (data not shown). In
silico analysis identified a region ( 2216 to  2211)
within the 94 bp sequence that differs by 1 bp from a
consensus site for GATA factors (Fig. 5A). This was of
interest, because GATA 4 and GATA 6 expression increases
when EC cells undergo differentiation (Morrisey et al.,
1996; Murakami et al., 1999). However, overexpression of
neither GATA 4 nor GATA 6 influenced Elf3 promoter
activity in F9-differentiated cells (data not shown). Interest-
ingly, this region of the Elf3 gene contains near perfect 7 bp
repeats that differ from one another by only 1 bp, and which
are separated from each other by 8 bp (Fig. 5A). However,
these sequences do not appear to match the consensus
sequence for any known eukaryotic transcription factor.
4. Discussion
Previous studies have shown that Elf3 mRNA increases
at least sixfold after EC cells differentiate (Kim et al.,
2002). However, changes in Elf3 protein levels in this
model system have not been determined due to the lack of
an antibody that is specific for mouse Elf3. In this study,
we examined the DNA regulatory regions that influence
the expression of the Elf3 gene. Specifically, we mapped
the transcription start site of the murine Elf3 gene in F9-
differentiated cells and identified cis-regulatory elements
located in the proximal promoter region as well as in a
region 2 kb upstream of the transcription start site. The
upstream regulatory region is localized to a 36 bp se-
quence, which appears to play an important role in
upregulation of Elf3 when F9 EC cells differentiate.
In this study, 5V-RACE identified a major transcription
start site for the murine Elf3 gene in F9-differentiated
cells at position + 32, which is 30 bp downstream from
the center of a TATA box at + 2. In our study, 16 of the
17 isolated clones identified a start site at position + 32,
while the remaining clone corresponded to a start site at
+ 33. In contrast to our findings, Tymms et al. (1997)
used 5V-RACE and mapped the dominant start site in
adult murine lung tissue to + 51. In their study, a total of
seven clones were sequenced, and four of the seven
clones identified a transcription start site at position
+ 51. The remaining three clones identified start sites at
positions + 42, + 44 and + 68, respectively. An analysis
of hundreds of genes by Bucher (1990) found the center-
to-center spacing between a TATA box and the cap signal
to be 30F 2 bp. It is possible that multiple start sites are
used for the Elf3 gene and that different start sites are
used in different cell types. However, if functional, the
TATA box would direct transcriptional initiation to the
site that we identified in F9-differentiated cells rather
than to the site found in adult lung. Two studies of the
human ELF3 gene have mapped the transcription start
site to  7 in adult liver cells (Oettgen et al., 1999) and
 8 in a gastric cancer cell line (Park et al., 2001).
Oettgen et al. (1999) point out that the difference in start
site between the human and murine genes is likely due to
the presence of a second TATA box centered at  39 in
the human sequence, which is not present in the murine
sequence.
The DNA sequences of the four promoter-proximal
cis-regulatory elements (ESE, POU, nB and CCAAT box)
shown to be functional in F9-differentiated cells (Fig. 2)
are 100% conserved between the mouse and human
except for one base pair in the ESE site (Neve et al.,
1998). This is also true for an overlapping CG box and
USF site, but disruption of either site on its own or in
Fig. 5. Mutational analysis of the upstream 94 bp positive regulatory region.
(A) The murine 94 bp upstream enhancer region is shown. Sixteen
sequences chosen for mutational analysis are sequentially numbered and
underlined. A potential GATA site is shown in bold and a repeated sequence
is marked with an upper bracket. The single difference in the 7 bp repeat is
labeled with an‘‘*’’ (B) F9-differentiated cells were transfected with the
wild-type (mElf3 2236/ + 703D 2142/ 339) or mutant promoter/reporter
constructs containing Elf3 sequence from  2236 to  2143 inserted
upstream of the mElf3 338/ + 703 construct. In each numbered construct,
the sequence to be mutated was replaced by the sequence 5V-CCCGGG-3V.
Cells were assayed for luciferase activity as described in Materials and
methods. Values for the mutant constructs were compared to mElf3 338/
+ 703, shown as ‘‘C’’, which was set to 1. The values shown are
averagesF S.E.M. for triplicate samples from a representative experiment.
This experiment was performed four times with similar results.
J. Hou et al. / Gene 340 (2004) 123–131 129
combination failed to affect Elf3 promoter activity in F9-
differentiated cells (data not shown). In contrast to these
sites, disruption of the nB site and the ESE site reduced
Elf3 promoter activity 43% and 48%, respectively, (Fig.
2). Earlier studies demonstrated that both sites are func-
tional in the case of the human gene. The nB site was
first shown to be functional in the case of the human
ELF3 promoter using a mouse monocytic cell line (Rud-
ders et al., 2001). This study also reported that the nB
site of the human ELF3 gene binds the p50 and p65
subunits of NF-nB in vitro (Rudders et al., 2001).
Moreover, recent evidence argues strongly that p50 and
p65 activate the human ELF3 promoter via the nB site in
vivo (Grall et al., 2003). Similar to these findings, we
determined that c-Rel and the p50 subunit of NF-nB
present in nuclear extracts from F9-differentiated cells
can bind to the nB site in vitro (data not shown). The
ESE site in the human ELF3 gene was also shown to be
functional in an earlier study that used a human gastric
tumor cell line (Park et al., 2001). Interestingly, disruption
of the ESE site reduced the activity of the human ELF3
promoter approximately 80% in the gastric tumor cell
line. Thus, the overall contribution of the ESE site may
differ between the human and the murine gene and/or in
different cell types (48% for F9-differentiated cells vs.
80% for gastric tumor cells). Thus far, the nuclear factor
shown previously to bind to the ESE site in vitro has not
been identified (Park et al., 2001). Given that the ESE
site influences Elf3 promoter activity in at least two cell
types, the factor that binds to the ESE site warrants
further study. However, it would appear that these studies
would be best undertaken using gastric tumor cells.
In this study, we provide the first demonstration that
the POU motif and the CCAAT box of this gene influence
its promoter activity. Disruption of either site reduced Elf3
promoter activity more than 65% in F9-differentiated cells.
In the case of the CCAAT box, we determined by
chromatin immunoprecipitation that NF-Y binds to the
promoter of the endogenous Elf3 gene in F9-differentiated
cells, and we determined that NF-Y mediates the positive
effect of the CCAAT box with the use of a dominant-
negative mutant of NF-YA (Mantovani et al., 1994; data
not shown). In other work not described in this report, we
determined by electrophoretic mobility shift assay that the
transcription factor Oct-1 in nuclear extracts prepared from
F9-differentiated cells can bind to the POU motif of the
Elf3 gene in vitro. Given the importance of the POU
motif, future studies should determine whether Oct-1 binds
to the POU motif in F9-differentiated cells and elevates
Elf3 promoter activity in vivo.
The work reported in this study argues strongly that an
upstream regulatory region plays an important role in
elevating Elf3 promoter activity after EC cells undergo
differentiation. Earlier studies demonstrated that the
steady-state level of Elf3 mRNA increases after EC cells
are induced to differentiate, reaching levels approximately
sixfold higher after 3 days and eightfold higher after 5
days (Kim et al., 2002). In the present study, after 3 days
of differentiation, the activity of promoter/reporter con-
structs containing the upstream region is elevated fivefold,
while the activity of the proximal promoter appears to
increase only twofold (Fig. 3A). We localized this positive
regulatory region to a 94 bp sequence between  2236
and  2143 by using a battery of Elf3 promoter/reporter
gene constructs containing the proximal promoter and
various portions of the 5V-flanking region of the Elf3
gene. In F9-differentiated cells, constructs containing this
94 bp region have four- to sixfold higher activities than
constructs without this region. This is in contrast to F9 EC
cells, where both sets of constructs have similar activities
(Fig. 4C). Together, our data argue that differentiation of
EC cells significantly increases the activity of the Elf3
promoter and that full promoter activity is dependent on a
distal regulatory region located 2 kb upstream of the
transcription start site of Elf3. Interestingly, this regulatory
region functions in a distance-independent manner, given
that it functions even when it is placed 2 kb closer to the
Elf3 promoter (Fig. 4B). We also believe that this region is
likely to function in an orientation-independent manner,
but this was not tested in this study.
Saturation mutagenesis of the 94 bp regulatory region
identified a core of 36 bp from  2215 to  2180, which
is required for full Elf3 promoter activity. The importance
of this 36 bp region was demonstrated by six sequential 6
bp mutations, each of which reduced Elf3 promoter
activity. Given that the size of this region is far greater
than the size of a typical transcription factor binding site
(4–10 bp), and the fact that cis-regulatory elements are
often clustered in enhancers, we anticipate that more than
one transcription factor binds to this regulatory region.
Thus far, we have been unable to identify the factors
involved. Efforts to identify proteins that bind to this 36
bp region using electrophoretic mobility shift assay have
not been successful.
In conclusion, the work reported in this study establishes
that the promoter of the murine Elf3 gene in F9-differenti-
ated cells is controlled by at least four cis-regulatory
elements located within 250 bp of the transcription start
site. Moreover, we have identified a novel 36 bp regulatory
region, which is located 2 kb upstream of the transcription
start site. Importantly, this regulatory region exerts a strong
influence on the Elf3 promoter activity in F9-differentiated
cells and appears to play an important role in the upregu-
lation of Elf3 gene expression after EC cells undergo
differentiation. Given that these cells provide an excellent
model for mammalian embryogenesis and that differentia-
tion of EC cells strongly suppresses their tumorigenicity
(Adamson and Graham, 1980), it will be of interest to better
understand how the Elf3 gene is regulated in this model
system. Such an understanding is likely to provide impor-
tant insights into the regulation of this gene in both normal
and diseased tissues.
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